RNA structure may trigger harmful protein clumps in brain cells

A recent study from Kumamoto University suggests that a specific RNA structure, called G-quadruplex (G4), could play a role in the development of Parkinson’s disease by creating a "scaffold" for harmful protein clumps in nerve cells. These protein clumps, primarily made up of a protein called alpha-synuclein, are toxic to neurons and are linked to the movement and coordination issues seen in Parkinson’s. Researchers found that under cellular stress, high calcium levels can cause RNA molecules to form G4s. These structures seem to attract alpha-synuclein, encouraging it to clump together in a way that damages neurons. In lab tests with nerve cells, they observed that when G4s were present, alpha-synuclein clumps formed, disrupting normal cell communication. The researchers used a light-based technique to trigger G4s, which led to persistent alpha-synuclein clumping even after the light was turned off—indicating that the clumps were stable and likely permanent. To test this in a living model, they used mice with Parkinson’s-like symptoms and observed similar damage to nerve cells when G4s were active. The clumping of alpha-synuclein was associated with the death of neurons that produce dopamine—a brain chemical essential for movement control. This neuron death in the mice led to movement difficulties resembling Parkinson’s symptoms. Excitingly, the team found that a compound called 5-aminolevulinic acid (5-ALA) could inhibit the formation of G4 structures. When they treated Parkinson’s-model mice with 5-ALA, they saw a reduction in alpha-synuclein clumping, less nerve cell death, and improved motor function over two months. Because 5-ALA can cross into the brain and has minimal side effects, it may offer a potential preventive treatment for Parkinson’s and possibly other neurodegenerative diseases, including Alzheimer’s. These findings point to G4s as promising targets for early intervention in Parkinson’s, opening up new possibilities for treatment approaches. Further research is needed to confirm the effectiveness of 5-ALA in humans, but the study is a promising step toward new therapies for managing Parkinson’s disease.